<DOC>
	<DOC>NCT03078881</DOC>
	<brief_summary>This is a Pre-Phase 1 prospective, non-interventional clinical assessment study to evaluate Crigler-Najjar syndrome subjects requiring daily phototherapy, aged 1 year and older.</brief_summary>
	<brief_title>Clinical Assessment Study in Crigler-Najjar Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Crigler-Najjar Syndrome</mesh_term>
	<criteria>Key Subject has a diagnosis of CriglerNajjar syndrome resulting from a confirmed mutation in the UGT1A1 gene Subject is aged equal or greater than 1 year of age Subject receives daily phototherapy for a minimum of 6 hours within a 24hour period (daily illumination time) Subject is currently participating in an interventional study or has received gene or cell therapy Subject has received a whole liver, partial liver, or hepatocyte transplant; or subject has a liver transplant scheduled within the planned participation period of this study Subject has significant cholestatic disease, in the opinion of the investigator Subject is receiving phenobarbital or other known inducer of UGT1A1 within 30 days of screening Subject has any clinically significant underlying liver disease (other than CriglerNajjar syndrome), in the opinion of the investigator Subject has a history of, or currently has, a clinically important condition other than CriglerNajjar syndrome, in the opinion of the investigator</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>